What kind of patients need to take neratinib/neratinib?

Neratinib/Neratinib is an oral drug and one of the targeted therapy drugs widely used in clinical practice. It is mainly used in the treatment of breast cancer, especially HER2-positive breast cancer.

HER2-positive breast cancer is a subtype of breast cancer that affects approximately 15-20% of breast cancer patients. Under normal circumstances, the HER2 gene can control the process of cell growth and spread, but when the gene is mutated or overexpressed, it can cause abnormal cell proliferation and form tumors. Neratinib mainly interferes with the growth and spread of cancer cells by inhibiting the activity of the HER2 signaling pathway, thereby achieving the purpose of treatment. Patients who need to use neratinib mainly include:

1. Patients with HER2-positive breast cancer who have experienced breast cancer surgery, radiotherapy and other systemic treatments in the past. Neratinib is often used as adjuvant therapy, a procedure used after surgery or radiation therapy to prevent cancer from coming back.

2. For patients with HER2-positive breast cancer, neratinib is used as a single agent for the long-term adjuvant treatment of adult patients with early-stage HER2-positive breast cancer to receive trastuzumab-based adjuvant therapy.

3. Patients with advanced or metastatic HER2-positive breast cancer: Neratinib can be combined with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more previous anti-HER2-based regimens in the metastatic setting. Neratinib can be used as a maintenance treatment option to help control tumor progression and extend survival.

Neratinib is not suitable for all breast cancer patients. Before deciding to use neratinib, doctors will comprehensively consider the patient's specific situation, including age, disease severity, previous treatment effects and other factors. In addition, neratinib may cause some side effects, such as nausea, vomiting, diarrhea, fatigue, etc., so patients need to monitor closely during use and report any discomfort symptoms to their doctor in a timely manner.